RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance

Salm, F; Cwiek, P; Ghosal, A; Lucia Buccarello, A; Largey, F; Wotzkow, C; Höland, K; Styp-Rekowska, B; Djonov, V; Zlobec, I; Bodmer, N; Gross, N; Westermann, F; Schäfer, S C; Arcaro, A (2012). RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene, 32(34), pp. 3944-3953. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2012.416

Full text not available from this repository.

Chemotherapeutic drug resistance is one of the major causes for treatment failure in high-risk neuroblastoma (NB), the most common extra cranial solid tumor in children. Poor prognosis is typically associated with MYCN amplification. Here, we utilized a loss-of-function kinome-wide RNA interference screen to identify genes that cause cisplatin sensitization. We identified fibroblast growth factor receptor 2 (FGFR2) as an important determinant of cisplatin resistance. Pharmacological inhibition of FGFR2 confirmed the importance of this kinase in NB chemoresistance. Silencing of FGFR2 sensitized NB cells to cisplatin-induced apoptosis, which was regulated by the downregulation of the anti-apoptotic proteins BCL2 and BCLX(L). Mechanistically, FGFR2 was shown to activate protein kinase C-δ to induce BCL2 expression. FGFR2, as well as the ligand fibroblast growth factor-2, were consistently expressed in primary NB and NB cell lines, indicating the presence of an autocrine loop. Expression analysis revealed that FGFR2 correlates with MYCN amplification and with advanced stage disease, demonstrating the clinical relevance of FGFR2 in NB. These findings suggest a novel role for FGFR2 in chemoresistance and provide a rational to combine pharmacological inhibitors against FGFR2 with chemotherapeutic agents for the treatment of NB.Oncogene advance online publication, 1 October 2012; doi:10.1038/onc.2012.416.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Anatomy 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine 04 Faculty of Medicine > Service Sector > Institute of Pathology
UniBE Contributor:	Salm, Fabiana, Höland, Katrin, Djonov, Valentin Georgiev, Zlobec, Inti, Arcaro, Alexandre
Subjects:	600 Technology > 610 Medicine & health
ISSN:	0950-9232
Publisher:	Nature Publishing Group
Language:	English
Submitter:	Anette van Dorland
Date Deposited:	04 Oct 2013 14:32
Last Modified:	05 Dec 2022 14:10
Publisher DOI:	10.1038/onc.2012.416
PubMed ID:	23027129
Web of Science ID:	000323748100003
URI:	https://boris.unibe.ch/id/eprint/12495 (FactScience: 218847)